Kanno H, Kitami K, Senga Y, Takahashi T, Nagashima Y
Department of Urology, International Goodwill Hospital.
Hinyokika Kiyo. 1993 Aug;39(8):725-9.
We report a case of renal cell carcinoma in a 76-year-old man with pulmonary metastasis and tumor thrombus in inferior vena cava. The patient responded to the combination therapy with a small amount of HLBI (human lymphoblastoid interferon-alpha) and UFT (1:4 mixture of tegafur and uracil). HLBI was administered intramuscularly at a dose of 3 x 10(6) IU two times a week. However, the administration of the same dose was discontinued, because of the severe side effects, such as depression, general fatigue, anorexia and high fever. Finally, the maximum dose was determined to be 2 x 10(6) IU/week. Nine weeks after the first treatment, UFT was simultaneously given orally at a dose of 100 mg/day for potentiating the antitumor effect. At 12 weeks, the patient registered complete response of pulmonary metastasis, and partial response (83% reduction) of renal tumor. About 60 x 10(6) IU HLBI was administered until the response was noted. After 34 weeks of administration of HLBI, nephrectomy was performed. Histological diagnosis was renal cell carcinoma of clear cell subtype, grade 2. Microscopically, many lymphocytes infiltrated into the cancer cells. This suggests the possibility of immunological response caused by HLBI.
我们报告了一例76岁男性肾细胞癌患者，该患者伴有肺转移及下腔静脉肿瘤血栓形成。患者接受了小剂量人淋巴母细胞样α干扰素（HLBI）与优福定（替加氟与尿嘧啶1:4的混合物）的联合治疗。HLBI通过肌肉注射给药，剂量为3×10⁶国际单位，每周两次。然而，由于出现严重副作用，如抑郁、全身乏力、厌食和高热，相同剂量的给药被中断。最终，确定最大剂量为2×10⁶国际单位/周。首次治疗9周后，同时口服优福定，剂量为100毫克/天，以增强抗肿瘤效果。12周时，患者肺部转移灶达到完全缓解，肾肿瘤部分缓解（缩小83%）。在观察到疗效之前，共给予约60×10⁶国际单位的HLBI。HLBI给药34周后，进行了肾切除术。组织学诊断为透明细胞亚型2级肾细胞癌。显微镜下可见许多淋巴细胞浸润到癌细胞中。这提示HLBI引起免疫反应的可能性。
